ATXS
Price
$5.81
Change
+$0.08 (+1.40%)
Updated
Jul 3 closing price
Capitalization
327.88M
36 days until earnings call
PHAR
Price
$10.58
Change
-$0.07 (-0.66%)
Updated
Jul 3 closing price
Capitalization
723.01M
25 days until earnings call
Interact to see
Advertisement

ATXS vs PHAR

Header iconATXS vs PHAR Comparison
Open Charts ATXS vs PHARBanner chart's image
Astria Therapeutics
Price$5.81
Change+$0.08 (+1.40%)
Volume$188.85K
Capitalization327.88M
Pharming Group
Price$10.58
Change-$0.07 (-0.66%)
Volume$344
Capitalization723.01M
ATXS vs PHAR Comparison Chart in %
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHAR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. PHAR commentary
Jul 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Hold and PHAR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 06, 2025
Stock price -- (ATXS: $5.81 vs. PHAR: $10.58)
Brand notoriety: ATXS and PHAR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 40% vs. PHAR: 9%
Market capitalization -- ATXS: $327.88M vs. PHAR: $723.01M
ATXS [@Biotechnology] is valued at $327.88M. PHAR’s [@Biotechnology] market capitalization is $723.01M. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whilePHAR’s FA Score has 1 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • PHAR’s FA Score: 1 green, 4 red.
According to our system of comparison, PHAR is a better buy in the long-term than ATXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 6 TA indicator(s) are bullish while PHAR’s TA Score has 2 bullish TA indicator(s).

  • ATXS’s TA Score: 6 bullish, 4 bearish.
  • PHAR’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, ATXS is a better buy in the short-term than PHAR.

Price Growth

ATXS (@Biotechnology) experienced а +6.80% price change this week, while PHAR (@Biotechnology) price change was -2.22% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

ATXS is expected to report earnings on Nov 12, 2025.

PHAR is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PHAR($723M) has a higher market cap than ATXS($328M). PHAR YTD gains are higher at: 5.117 vs. ATXS (-35.011). PHAR has higher annual earnings (EBITDA): 21.4M vs. ATXS (-124.4M). ATXS has more cash in the bank: 295M vs. PHAR (107M). ATXS has less debt than PHAR: ATXS (5.06M) vs PHAR (119M). PHAR has higher revenues than ATXS: PHAR (321M) vs ATXS (0).
ATXSPHARATXS / PHAR
Capitalization328M723M45%
EBITDA-124.4M21.4M-581%
Gain YTD-35.0115.117-684%
P/E RatioN/AN/A-
Revenue0321M-
Total Cash295M107M276%
Total Debt5.06M119M4%
FUNDAMENTALS RATINGS
ATXS: Fundamental Ratings
ATXS
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
55
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ATXSPHAR
RSI
ODDS (%)
Bearish Trend 4 days ago
77%
Bearish Trend 4 days ago
73%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 4 days ago
76%
Momentum
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
84%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
80%
Bearish Trend 4 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
84%
Bearish Trend 4 days ago
81%
Advances
ODDS (%)
Bullish Trend 4 days ago
79%
N/A
Declines
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 4 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
84%
Bearish Trend 4 days ago
83%
Aroon
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 4 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHAR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DASTF36.690.88
+2.46%
Dassault Systemes SA
RELV2.31N/A
N/A
Reliv International, Inc.
AMVMF25.43N/A
N/A
AMG Advanced Metallurgical Group NV
SABK16.00N/A
N/A
South Atlantic Bancshares, Inc.
TMICF67.53N/A
N/A
Trend Micro Inc.

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with XENE. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
+1.40%
XENE - ATXS
53%
Loosely correlated
-0.33%
CRNX - ATXS
53%
Loosely correlated
+1.22%
DNLI - ATXS
52%
Loosely correlated
-1.41%
ERAS - ATXS
52%
Loosely correlated
-0.69%
COGT - ATXS
52%
Loosely correlated
+2.29%
More

PHAR and

Correlation & Price change

A.I.dvisor tells us that PHAR and APLM have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PHAR and APLM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHAR
1D Price
Change %
PHAR100%
-0.66%
APLM - PHAR
31%
Poorly correlated
-6.40%
ADPT - PHAR
27%
Poorly correlated
+2.79%
IBRX - PHAR
27%
Poorly correlated
+3.03%
ATXS - PHAR
26%
Poorly correlated
+1.40%
SONN - PHAR
25%
Poorly correlated
-5.54%
More